Evidence method
Level · gp.fundamentals.debt_to_revenue
43.89% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Jun 30, 2018
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000105770-18-000032General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
4.51% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
18.32% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.shares_outstanding
-0.63% · CORE · VALID
Evidence method
Yoy · gp.fundamentals.revenue
12.55% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
46.53% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
31.78% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
13.47% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.41% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
1.34% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 6.74%
- Current
- 4.51%
- Delta
- -2.22%
- Previous
- 10.83%
- Current
- 18.32%
- Delta
- 7.50%
- Previous
- 0.03%
- Current
- -0.63%
- Delta
- -0.66%
- Previous
- 7.22%
- Current
- 12.55%
- Delta
- 5.33%
- Previous
- 51.89%
- Current
- 46.53%
- Delta
- -5.36%
- Previous
- 32.33%
- Current
- 31.78%
- Delta
- -0.55%
- Previous
- 12.85%
- Current
- 13.47%
- Delta
- 0.63%
- Previous
- 2.31%
- Current
- 2.41%
- Delta
- 0.10%
- Previous
- 0.82%
- Current
- 1.34%
- Delta
- 0.52%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · WST Fundamental State →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST CASH_GENERATION_INCREASED →Transitioned To · WST DILUTION_DECREASED →Transitioned To · WST SBC_INTENSITY_INCREASED →Transitioned To · WST Fundamental State →Transitioned To · WST CAPEX_INTENSITY_DECREASED →Transitioned To · WST GROWTH_INCREASED →Transitioned To · WST INVENTORY_PRESSURE_DECREASED →Transitioned To · WST MARGIN_DECREASED →Transitioned To · WST PROFITABILITY_INCREASED →Transitioned To · WST R_AND_D_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.